Neovascular age-related macular degeneration is characterized by the growth of abnormal, choroidal blood vessels beneath the macula. When left untreated, these blood vessels can lead to severe loss of vision. Intravitreal injection of anti-vascular endothelial growth factor-A drugs is an established therapy that helps to prevent the growth of these abnormal vessels. In the United Kingdom, this treatment is provided for patients with visual acuity in the range of 6/12-6/96, consistent with the pivotal trials that were conducted to approve the use of this therapy. As the use of intravitreal therapy for age-related macular degeneration has increased, studies have suggested that starting treatment earlier in the disease process, before patients have significant vision loss, can help to preserve vision longer. In this study, the authors used data from thousands of patients from multiple health centers in the United Kingdom to further evaluate this effect on a large scale.
Continue reading "UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12"UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12
